Prokidney (PROK) Invested Capital (2021 - 2022)
Prokidney's (PROK) quarterly Invested Capital came in at $6.6 million in Q2 2022, down 58.39% year-over-year from $15.9 million in Q2 2021, and down 67.26% quarter-over-quarter from $20.2 million in Q1 2022.
Powered by 
Analysis
Prokidney (PROK) Invested Capital (2021 - 2022) Analysis & Trends
Prokidney (PROK) has reported Invested Capital for 2 consecutive years, with $6.6 million the latest figure, recorded in Q2 2022.
- On a quarterly basis, Invested Capital fell 58.39% year-over-year to $6.6 million in Q2 2022; TTM through Jun 2022 was $6.6 million, a 58.39% decrease from a year earlier, with the FY2021 full-year figure at $26.9 million, changed N/A from the prior year.
- Invested Capital was $6.6 million for Q2 2022 at Prokidney, down from $20.2 million in the prior quarter.
- Over five years, Invested Capital peaked at $26.9 million in Q4 2021 and troughed at $6.6 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 2.33 Bn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.39 Bn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 374.20 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 1.18 Bn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 137.46 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 2.38 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | - |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 6.62 Mn |
| Mar 31, 2022 | 20.21 Mn |
| Dec 31, 2021 | 26.93 Mn |
| Sep 30, 2021 | 10.45 Mn |
| Jun 30, 2021 | 15.91 Mn |